Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.37 |
| ▸ | UCHL1 | P09936 | 4/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1273270 | 1.00 | NR1H2 (0.40) | NR1H2NR1H3USP30UCHL1GPR119 | |
| SCHEMBL1273394 | 1.00 | NR1H2 (0.40) | NR1H2NR1H3USP30UCHL1GPR119 | |
| SCHEMBL1275274 | 0.87 | USP30 (0.43) | NR1H2NR1H3USP30UCHL1GPR119 | |
| SCHEMBL1275276 | 0.87 | USP30 (0.43) | NR1H2NR1H3USP30UCHL1GPR119 | |
| SCHEMBL1273546 | 0.83 | NR1H2 (0.57) | NR1H2NR1H3USP30UCHL1 | |
| SCHEMBL1273399 | 0.83 | NR1H2 (0.57) | NR1H2NR1H3USP30UCHL1 | |
| SCHEMBL1273870 | 0.82 | ALDH1A1 (0.35) | USP30UCHL1GPR119L3MBTL1 | |
| SCHEMBL1273532 | 0.82 | NR1H2 (0.41) | NR1H2NR1H3UCHL1GPR119 | |
| SCHEMBL1271997 | 0.81 | NR1H2 (0.44) | NR1H2NR1H3USP30UCHL1L3MBTL1 | |
| SCHEMBL1273365 | 0.81 | NR1H2 (0.44) | NR1H2NR1H3USP30UCHL1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | BIRC5, XIAP, BIRC2 | NR1H2 4004/4885NR1H3 4178/4885USP30 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.